Targeted Panel Development | Native-Read Sequencing

Products

Services

Applications

Company

Resources

Contact

Applications
Applications
Telomeres, the protective caps at the end of our chromosomes, sit at the intersection of aging, cancer, and neurodegeneration research.
Telomeres, the protective caps at the end of our chromosomes, sit at the intersection of aging.
Research & Translation
Biopharma Research
Clinical Development

Products
Products
Explore our advanced sequencing products for turning complex molecular signals into high-confidence readouts across clinical testing, RNA quality control, and translational methylation programs.
View Our Additional Services
NeuroLens®
Neuron Cell-Death Test
RNA Clarity™
RNA Vaccine QC
MethylMap™
Native-Read Methylation Sequencing

Services
Services
End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis, from experimental design and assay development to bioinformatics, interpretation, and data delivery.
Native-Read Multiomic Sequencing
Direct Whole Methylome Sequencing (gDNA)
Direct Methylation Sequencing (cfDNA)
Direct Targeted Methylation Sequencing (gDNA)
Whole Genome Sequencing
RNA Sequencing
Direct RNA Sequencing
cDNA Sequencing
Specialized Services
Telomere Sequencing
Proteomics (available soon)

Applications
Applications
Explore how our products and services help solve difficult biological and genomic problems, from liquid biopsy signals to complex regions and emerging biomarker development.
Hard-to-Sequence Genes & Complex Regions
Liquid Biopsy cfDNA Analysis
Targeted Panel Development

Company
Company
Building the future of precision diagnostics through sequencing innovation, scientific rigor, and collaborative partnerships.
About Us
Team

For multiomic research and translational applications requiring analysis of specific genes, regions, variants, and epigenetic signatures, whole-genome sequencing approaches are often cost-prohibitive and difficult to scale.
Renew provides targeted native-read sequencing solutions for gDNA and cfDNA that preserve integrated genomic and epigenetic insights while enabling higher-throughput, cost-effective interrogation of regions of interest.
Through collaborations with Agilent Technologies and Twist Bioscience, Renew supports custom panel development from design and optimization through validation, sequencing, bioinformatics, and reporting, helping teams move targeted multiomic assays from concept to deployment.

Start A Project

One Custom Panel Framework, Two Targeting Strategies

Integrated Genomics + Epigenomics

Agilent-Enabled Native-Read Targeting

Combines Agilent SureSelect hybridization capture, Renew library preparation, and native nanopore sequencing to preserve native DNA structure and epigenetic signals. Ideal for applications requiring integrated analysis of variants, haplotypes, STRs, and regional methylation from the same dataset.

Complex Variant Resolution

Twist Bioscience Certified Targeting

Combines Twist PCR target enrichment, Renew library preparation, and long-read nanopore sequencing to generate longer target-spanning reads. Ideal for phasing, repeat resolution, CNV assessment, hybrid gene characterization, and structural variant analysis where read length is prioritized over native epigenetic information

Flexible, Scalable Long-Read Resolution

Renew integrates custom panel design, hybridization-based target enrichment, native-read sequencing, bioinformatics, validation, and reporting within a CLIA-certified, CAP-accredited laboratory, simplifying the path from assay design to deployment

This Approach Enables

Custom panel design matched to biology, budget, and intended use

Targeted genomic and epigenetic analysis without unnecessary whole-genome sequencing

Integrated assay development, sequencing, bioinformatics, and reporting under one roof

Which Is Supports

Scalable studies across exploratory, retrospective, and prospective cohorts

Customer-specific endpoints, outputs, and reporting requirements

Verification, validation, and clinical research deployment in a CLIA/CAP setting

Applications

Renew has applied this model across targeted methylation and pharmacogenomics panels spanning SNVs, STRs, haplotypes, CNVs, hybrid genes, and regional methylation, demonstrating the versatility of targeted native-read multiomics across research, translational, and clinical settings.

Traditional methylation profiling relies on bisulfite conversion, PCR amplification, or methylation-specific enrichment methods that can introduce bias, damage DNA. Renew’s Direct Targeted Methylation Sequencing (dTMS) enables high-depth interrogation of genomic regions of interest while preserving native methylation information.

By combining Agilent SureSelect target enrichment with native nanopore sequencing, dTMS enabled accurate regional methylation analysis across targeted genomic regions. For this application, Agilent's SureSelect MethylSeq DMR panel was applied to gDNA from the well-characterized HG002 reference cell line (Genome in a Bottle, GIAB)

Figure 1. Regional methylation measurements generated by targeted native-read sequencing demonstrate strong concordance with methylation standards. Regional methylation values showed high agreement with reference methylation measurements across targeted loci (R² ≥ 0.99), supporting accurate and reproducible regional methylation profiling using targeted native-read sequencing.

Where allele structure directly impacts clinical interpretation, long-read sequencing provides critical resolution. While many pharmacogenes can be assessed with short-read methods, structurally complex loci containing duplications, hybrid alleles, and phased variants, such as CYP2D6, HLA, UGT1A1, and select DPYD/TPMT contexts, often require long-read context.

A 49-gene pharmacogenomics panel was developed using Twist Bioscience PCR-based target enrichment and Oxford Nanopore long-read sequencing. Performance was evaluated across GIAB and Coriell reference samples, supporting accurate haplotype, copy number, and structural variant characterization in clinically relevant PGx genes.

Table comparing expected and called CYP2D6 genotypes for various cell lines with replicates and barcodes.

Figure 2. Long-read sequencing enables accurate CYP2D6 haplotype and structural variant resolution. Per-sample CYP2D6 star-allele calls, including copy number changes and hybrid alleles (e.g., *1/*4x2, *36+*10), were compared with expected haplotypes across reference samples (GIAB, Coriell; ≥30x coverage). High concordance was observed, demonstrating accurate resolution of clinically relevant pharmacogenomic haplotypes and structural variation.

Renew combines platform flexibility, nanopore expertise, and operational excellence to resolve areas of the genome that standard approaches cannot.